Advertisement
Advertisement
Aeglea BioTherapeutics, Inc. (AGLE)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
As of 10:59AM EDT. Market open.
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 0.4981 |
| Open | 0.5000 |
| Bid | 0.5000 x 800 |
| Ask | 0.5170 x 2200 |
| Day's Range | 0.4959 - 0.5200 |
| 52 Week Range | 0.4900 - 8.5000 |
| Volume | |
| Avg. Volume | 947,571 |
| Market Cap | 24.941M |
| Beta (5Y Monthly) | 1.43 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0390 |
| Earnings Date | Mar 16, 2022 - Mar 21, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.14 |
- Zacks
Celldex (CLDX) Down on Interim Data From Phase Ib Study in CSU
Celldex (CLDX) posts interim data from the phase Ib study evaluating barzolvolimab in patients with moderate to severe chronic spontaneous urticaria. Shares down.
- Zacks
Graybug (GRAY) to Review Strategic Alternatives, Stock Up
Graybug's (GRAY) board of directors is set to review strategic options focused on maximizing shareholder value, including a potential sale of the company. Shares rise.
- Zacks
Cybin (CYBN) Up on FDA Clearance of IND for CYB003 in MDD
Cybin (CYBN) receives a "may proceed letter" and IND application clearance from the FDA for a phase I/IIa study evaluating CYB003 for potential treatment of major depressive disorder. Shares up.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
